Abstract Background: Venous thromboembolism (VTE) is the third most frequent vascular disease worldwide; it is a significant preventable cause of in-hospital death. Early screening of DVT in high-risk groups is crucial to prevent the disease & its sequelae, D-dimer has the advantage of excluding venous thromboembolism (VTE) due to its high sensitivity. However, its low specificity is disadvantageous for diagnosing VTE. A method to increase the usefulness of D-dimer in the diagnosis of VTE is warranted. Aim of Study: Is to examine the possible role of the plasma level of SFMC & D-dimer in the prediction of hypercoagulable state and the subsequent VTE and to assess whether it can be used to indicate anticoagulant therapy. Patients and Methods: This cross sectional case control study on 85 subjects was performed at a vascular department between July 1, 2021 and December 31, 2021. Subjects were divided as: 60 patients with confirmed DVT positive by Compression ultrasonography (CUS) considered as patients group, and 25 apparently healthy individuals considered as control group with age and sex matched. For both groups levels of D-dimer and SFMC were measured simultaneously. Using ELISA kit supplied by SUNRED BIOTECHNOLOGY COMPANY China. Results: Compared with the control group, there was a statistically significant difference in levels of both SFMC & D-Dimer in the patient group (higher) than they were in control group. Conclusion: Monitoring serum DD and SFMC levels enables early detection and treatment intervention of VTE.